IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 26-50 out of 1353.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

Public Release: 22-Jun-2016
Nature Communications
Landmark study gives clearest picture of genetic causes of bowel cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer -- the UK's fourth most common cancer. The study examined all the genes from more than 1,000 people with bowel cancer and is the largest of its type ever conducted.
Cancer Research UK

Contact: Claire Hastings
chastings@icr.ac.uk
020-715-35380
Institute of Cancer Research

Public Release: 22-Jun-2016
Radiology
Has breast MRI been performed upside down?
A new phase 1 clinical trial from Brigham and Women's Hospital published in Radiology on June 22, 2016, evaluated the differences between pre-operative prone and supine MRI exams in 12 women undergoing lumpectomy for breast cancer. Researchers demonstrated that considerable deformity of the breast and tumor position occurs when patients are imaged in the prone position.
NIH/National Center for Research Resources, NIH/National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Breast Cancer Research Foundation

Contact: Elaine St. Peter
estpeter@partners.org
617-525-6375
Brigham and Women's Hospital

Public Release: 22-Jun-2016
The FEBS Journal
Low doses of common cancer drug may promote cancer spread
New research indicates that paclitaxel, which is the most commonly used chemotherapy for breast cancer, suppresses tumors when given at a certain dosage, but at low doses, it actually promotes cancer spread to the liver.

Contact: Penny Smith
sciencenewsroom@wiley.com
44-012-437-70171
Wiley

Public Release: 22-Jun-2016
Nature
Study finds contagious cancers are spreading among several species of shellfish
New research suggests that direct transmission of cancer among marine animals may be much more common than once thought.

Contact: Lucky Tran
lucky.tran@columbia.edu
212-305-2689
Columbia University Medical Center

Public Release: 22-Jun-2016
Nature
New knowledge about DNA repair can be turned into cancer inhibitors
Researchers at the University of Copenhagen have discovered a molecular mechanism that reads so-called epigenetic information and boosts repair of lesions in our DNA. This knowledge can be used to develop new targeted cancer treatment in which 'inhibitor molecules' can prevent cancer cells from repairing themselves. The researchers have taken out a patent for their new knowledge and the results have just been published in Nature.
European Research Council, Danish National Research Foundations Centre for Epigenetics, Danish Cancer Society, Danish Council for Independent Research/Medical Sciences, Novo Nordisk Foundation, Lundbeck Foundation, European Commission

Contact: Katrine Sonne-Hansen
katrine.sonne@bric.ku.dk
45-21-32-90-40
University of Copenhagen The Faculty of Health and Medical Sciences

Public Release: 22-Jun-2016
Oncotarget
Novel combination therapy developed at VCU Massey shows strong response in phase 1 trial
A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants.
National Institutes of Health, NIH/National Cancer Institute, Canadian Institutes of Health Research

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 22-Jun-2016
Nature
Sequencing method precise enough to reveal mechanisms by which bacteria resist antibiotics
A new technology can read the order (sequence) of the 'letters' making up DNA code with enough accuracy to reveal how bacteria use high-speed evolution to defeat antibiotics.
National Institutes of Health, Howard Hughes Medical Institute, Timur Artemyev

Contact: Greg Williams
gregory.williams@nyumc.org
212-404-3533
NYU Langone Medical Center / New York University School of Medicine

Public Release: 22-Jun-2016
Chemical Research in Toxicology
Hops could help reduce breast cancer risk
Hops, the flower cones used in beer-making, are also found in dietary supplements designed to help treat post-menopausal symptoms and other conditions. Scientists are now investigating whether an extract from the plant could also help fend off breast cancer. In the ACS journal Chemical Research in Toxicology, one team reports new lab tests on breast cells that support this possibility.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 22-Jun-2016
New England Journal of Medicine
High-tech scans can spare lymphoma patients intensive chemo
Hodgkin lymphoma patients can be spared the serious side effects of chemotherapy thanks to high-tech scans that can predict the outcome of treatment.
Cancer Research UK

Contact: Simon Shears
simon.shears@cancer.org.uk
44-203-469-8054
Cancer Research UK

Public Release: 21-Jun-2016
Immunity
CAR T cell therapy can now target solid tumors: Mouse study
Chimeric antigen receptor (CAR) T cell therapy, which edits a cancer patient's T cells to recognize their tumors, has successfully helped patients with blood cancers but has yet to show the ability to treat solid tumors. To overcome this hurdle, researchers genetically engineered human T cells to produce a CAR protein that recognizes a glycopeptide found on cancer cells but not normal cells, and then demonstrated its effectiveness in mice with leukemia and pancreatic cancer.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 21-Jun-2016
Immunity
New CAR T cell therapy using double target aimed at solid tumors
Chimeric antigen receptors engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. Researchers describe how an antibody that recognizes the combination of a known cancer-associated surface protein and a cancer-associated carbohydrate can be applied as a CAR-based therapy for a wide range of solid tumors.
National Institutes of Health, Danish Research Councils, Danish National Research Foundation

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 20-Jun-2016
Journal of the American Chemical Society
Rice University lab synthesizes new cancer fighter
Rice University scientists have synthesized a novel anti-cancer agent, Thailanstatin A, which was originally isolated from a bacterial species collected in Thailand.
Cancer Prevention and Research Institute of Texas, Welch Foundation

Contact: David Ruth
david@rice.edu
713-348-6327
Rice University

Public Release: 20-Jun-2016
Nature Medicine
'Holy grail' of breast cancer prevention in high-risk women may be in sight
Australian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.
National Breast Cancer Foundation, Qualtrough Cancer Research Fund, Joan Marshall Breast Cancer Research Fund, Australian Cancer Research Foundation, Cancer Council Victoria, Cancer Therapeutics Cooperative Research Centre, and others

Contact: Vanessa Solomon
solomon@wehi.edu.au
61-431-766-715
Walter and Eliza Hall Institute

Public Release: 20-Jun-2016
British Journal of Cancer
High blood sugar could mean lower risk of one type of brain tumor
In a surprising twist, benign brain tumors that have previously been tied to obesity and diabetes are less likely to emerge in those with high blood sugar, new research has found.
NIH/National Cancer Institute

Contact: Judith Schwartzbaum
Schwartzbaum.1@osu.edu
614-292-5152
Ohio State University

Public Release: 20-Jun-2016
Nucleic Acids Research
Understanding the resistance to treatments against breast cancer
Estrogens are responsible for the survival and proliferation of tumor cells in 70 percent of breast cancer cases. Nearly a third of the patients develop a resistance to anti-estrogen treatments such as tamoxifen after a few years. Biologists reveal how tumor cells become refractory to the drug. They succeeded in identifying eight factors involved in the process of resistance to the treatment. The researchers also suggest various approaches for developing new therapies.

Contact: Didier Picard
didier.picard@unige.ch
41-223-796-813
Université de Genève

Public Release: 20-Jun-2016
Proceedings of the National Academy of Sciences
New nanoparticle technology developed to treat aggressive thyroid cancer
Investigators at Brigham and Women's Hospital, together with collaborators from Massachusetts General Hospital, have developed an innovative nanoplatform that allows them to effectively deliver RNAi agents to the sites of cancer and suppress tumor growth and reduce metastasis in preclinical models of anaplastic thyroid cancer.
National Institutes of Health, DoD PCRP Synergistic Idea Development Award, the Koch-Prostate Cancer Foundation (PCF) Program in Nanotherapeutics, Movember-PCF Challenge Award, PCF Young Investigator Award, National Research Foundationof Korea

Contact: Haley Bridger
hbridger@partners.org
617-525-6383
Brigham and Women's Hospital

Public Release: 20-Jun-2016
JAMA Internal Medicine
Study finds patient navigators improve comprehensive cancer screening rates
A clinical trial conducted by Massachusetts General Hospital investigators has found that the use of patient navigators -- individuals who assist patients in receiving health care services -- may improve comprehensive cancer screening rates among patient populations not likely to receive recommended screenings.
American Cancer Society, Lazarex Cancer Foundation, Harvard Medical School Center for Primary Care Innovation Fellowship

Contact: Mike Morrison
mdmorrison@partners.org
617-724-6425
Massachusetts General Hospital

Public Release: 20-Jun-2016
Cancer Research
Tumor cells develop predictable characteristics that are not random, say Moffitt Cancer Center researchers
Moffitt Cancer Center researchers found that certain subpopulations can be predicted and do not develop randomly as previously thought.

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 20-Jun-2016
Lancet Oncology
New radiotherapy regime for prostate cancer could save NHS tens of millions per year
A shorter course of prostate cancer radiotherapy, involving fewer hospital visits and higher individual doses of radiotherapy, is as effective as the current standard treatment for both survival and quality of life, a major new study reports.
Cancer Research UK

Contact: Henry French
henry.french@icr.ac.uk
020-715-35582
Institute of Cancer Research

Public Release: 20-Jun-2016
Nature Cell Biology
Breast cancer cells use newfound pathway to survive low oxygen levels in tumors
Researchers have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors.
National Institutes of Health, Canadian Institutes of Health Research, Terry Fox New Frontiers Research Program, Cancer Research UK, Wellcome Trust, Kiban Kenkyu, Princess Margaret Cancer Foundation, Ontario Ministry of Health and Long Term Care, others

Contact: Greg Williams
gregory.williams@nyumc.org
212-404-3533
NYU Langone Medical Center / New York University School of Medicine

Public Release: 20-Jun-2016
Journal of Clinical Oncology
Study finds surgery can lengthen survival of metastatic kidney cancer patients
Researchers find cytoreductive nephrectomy may offer an overall survival benefit to patients with metastatic kidney cancer who are treated with targeted therapies.
Quebec Urological Association, The Trust Family, Loker Pinard, Dana-Farber/Michael Brigham Funds for Kidney Cancer Research, Dana-Farber/Harvard Cancer Center Kidney Cancer Program, and Dana-Farber/Harvard Cancer Center Kidney Cancer SPORE

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 20-Jun-2016
Leukemia
Fighting resistant blood cancer cells
Around 20 percent of adults diagnosed with leukemia suffer from chronic myeloid leukemia (CML). The protein Gab2 works as an enhancer of cancer-causing signals and is often present in larger quantities in CML cells than in healthy cells. In two studies, Freiburg researchers have made new discoveries concerning the relationship between CML and Gab2 and drugs that can break a particular resistance to Gab2 in CML cells.
Excellence Initiative of the German Research Foundation, Spemann Graduate School, José Carreras Leukämie Stiftung e.V., Deutsche Forschungsgemeinschaft, Heisenberg-Program, Centre for Biological Signalling Studies BIOSS

Contact: Katrin Albaum
katrin.albaum@bioss.uni-freiburg.de
49-761-203-97662
BIOSS - Centre for Biological Signalling Studies

Public Release: 17-Jun-2016
Clinical Cancer Research
The PI3K protein: A potential new therapeutic target in pancreatic neuroendocrine tumors
Researchers from Institute of Biomedical Investigation of Bellvitge have demonstrated that selective inactivation of the p110α PI3K isoform is sufficient to block tumor progression and metastasis in a mice model of PanNETs.

Contact: Gemma Fornons
gfornons@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 17-Jun-2016
British Journal of Cancer
Smoking can hamper common treatment for breast cancer
We know that individuals who smoke take major health risks. Now a new research study from Lund University in Sweden shows that common treatment for breast cancer works less well in patients who smoke, compared to non-smokers.

Contact: Cecilia Schubert
cecilia.schubert@kommunikation.lu.se
46-073-062-3858
Lund University

Public Release: 17-Jun-2016
Nature Medicine
Scientists discover mechanism of thalidomide
In the 1950s, thalidomide (Contergan) was prescribed as a sedative drug to pregnant women, resulting in a great number of infants with serious malformations. Up to now, the reasons for these disastrous birth defects have remained unclear. Researchers at the Technical University of Munich have at last identified the molecular mechanism of thalidomide. Their findings are highly relevant to current cancer therapies, as related substances are essential components of modern cancer treatment regimens.

Contact: Paul Hellmich
paul.hellmich@tum.de
49-892-892-2731
Technical University of Munich (TUM)

Showing releases 26-50 out of 1353.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

  Search News Releases

     

 

EurekAlert!